These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

118 related items for PubMed ID: 1908127

  • 1. Immunologic safety of recombinant factor VIII. The rFactor VIII Clinical Trial Group.
    Abildgaard CF.
    Semin Hematol; 1991 Apr; 28(2 Suppl 1):44. PubMed ID: 1908127
    [No Abstract] [Full Text] [Related]

  • 2. [Recombinant factor VIII].
    Tusell JM.
    Sangre (Barc); 1993 Apr; 38(2):139-42. PubMed ID: 8516727
    [No Abstract] [Full Text] [Related]

  • 3. Comments on the development of inhibitor antibodies in patients using recombinant factor VIII concentrates.
    Brettler DB.
    Semin Hematol; 1991 Apr; 28(2 Suppl 1):45-6. PubMed ID: 1908128
    [No Abstract] [Full Text] [Related]

  • 4. Clinical efficacy of recombinant factor VIII. The rFactor VIII Clinical Trial Group.
    Arkin S, Rose E, Forster A, Aledort LM.
    Semin Hematol; 1991 Apr; 28(2 Suppl 1):47-51. PubMed ID: 1908129
    [Abstract] [Full Text] [Related]

  • 5. Long-term persistence of anti-factor VIII antibody-secreting cells in hemophilic mice after treatment with human factor VIII.
    Hausl C, Maier E, Schwarz HP, Ahmad RU, Turecek PL, Dorner F, Reipert BM.
    Thromb Haemost; 2002 May; 87(5):840-5. PubMed ID: 12038787
    [Abstract] [Full Text] [Related]

  • 6. Impact of recombinant factor VIII on hemophilia care.
    Mannucci PM.
    Vox Sang; 1994 May; 67 Suppl 3():49-52. PubMed ID: 7975511
    [No Abstract] [Full Text] [Related]

  • 7. Factor VIII inhibitors in hemophilia.
    Mariani G.
    Bilt Hematol Transfuz; 1979 May; 7(1):3-41. PubMed ID: 121880
    [No Abstract] [Full Text] [Related]

  • 8. Design of clinical studies with recombinant factor VIII. The rFactor VIII Clinical Trial Group.
    Pennington JE, Schwartz RS.
    Semin Hematol; 1991 Apr; 28(2 Suppl 1):27-8. PubMed ID: 1908123
    [No Abstract] [Full Text] [Related]

  • 9. The pharmacokinetics of recombinant factor VIII. The rFactor VIII Clinical Trial Group.
    Harrison JF, Bloom AL, Abildgaard CF.
    Semin Hematol; 1991 Apr; 28(2 Suppl 1):29-35; discussion 36. PubMed ID: 1908124
    [No Abstract] [Full Text] [Related]

  • 10. [Porcine factor VIII].
    De Juan MJ, Montoro JB, Tusell JM.
    Sangre (Barc); 1991 Jun; 36(3):217-20. PubMed ID: 1948542
    [No Abstract] [Full Text] [Related]

  • 11. Zero incidence of inhibitors in previously untreated patients who received intermediate purity factor VIII concentrate or factor IX complex.
    Schimpf K, Schwarz P, Kunschak M.
    Thromb Haemost; 1995 Mar; 73(3):553-5. PubMed ID: 7667845
    [No Abstract] [Full Text] [Related]

  • 12. [Circulating anticoagulants in hemophilia A].
    Michalski R, Lopaciuk S.
    Acta Haematol Pol; 1973 Mar; 4(3):203-9. PubMed ID: 4800573
    [No Abstract] [Full Text] [Related]

  • 13. The use of porcine factor VIII concentrate (Hyate:C) in the treatment of patients with inhibitor antibodies to factor VIII. A multicenter US experience.
    Brettler DB, Forsberg AD, Levine PH, Aledort LM, Hilgartner MW, Kasper CK, Lusher JM, McMillan C, Roberts H.
    Arch Intern Med; 1989 Jun; 149(6):1381-5. PubMed ID: 2499293
    [Abstract] [Full Text] [Related]

  • 14. Prothrombin complex concentrates in hemophiliacs with inhibitors--a multicenter therapeutic trial.
    Lusher JM, Shapiro SS, Palascak JE, Rao AV, Levine PH, Blatt PM.
    Trans Assoc Am Physicians; 1980 Jun; 93():175-81. PubMed ID: 6787773
    [No Abstract] [Full Text] [Related]

  • 15. Blockade of CD40/CD40 ligand interactions prevents induction of factor VIII inhibitors in hemophilic mice but does not induce lasting immune tolerance.
    Reipert BM, Sasgary M, Ahmad RU, Auer W, Turecek PL, Schwarz HP.
    Thromb Haemost; 2001 Dec; 86(6):1345-52. PubMed ID: 11776297
    [Abstract] [Full Text] [Related]

  • 16. Is a change of factor VIII product a risk factor for the development of a factor VIII inhibitor?
    Baglin T, Beacham E.
    Thromb Haemost; 1998 Dec; 80(6):1036-7. PubMed ID: 9869186
    [No Abstract] [Full Text] [Related]

  • 17. [Treatment of hemophiliacs with antibodies to factor VIII].
    Evensen SA, Stavem P, Stormorken H, Glomstein A, Ly B.
    Tidsskr Nor Laegeforen; 1986 Jan 10; 106(1):35-8. PubMed ID: 3082032
    [No Abstract] [Full Text] [Related]

  • 18. [Factor VIII inhibitor in multitransfused hemophiliacs. A finding of varying therapeutic consequences].
    Ly B, Evensen SA, Stavem P.
    Tidsskr Nor Laegeforen; 1977 Apr 30; 97(12):554-6, 8. PubMed ID: 854906
    [No Abstract] [Full Text] [Related]

  • 19. Antibodies to heterologous proteins in hemophilia A patients receiving recombinant factor VIII (Recombinate).
    Ingerslev J, Christiansen K, Ravn HB, Bray GL, Gomperts ED, Recombinate Study Group.
    Thromb Haemost; 2002 Apr 30; 87(4):626-34. PubMed ID: 12008945
    [Abstract] [Full Text] [Related]

  • 20. T lymphocyte proliferative responses induced by recombinant factor VIII in hemophilia A patients with inhibitors.
    Singer ST, Addiego JE, Reason DC, Lucas AH.
    Thromb Haemost; 1996 Jul 30; 76(1):17-22. PubMed ID: 8819245
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.